Boeing's Supplier Ecosystem Rallies on Production Recovery, But Core Risks Remain

What happened

A recent Motley Fool article highlights that Boeing's production increases could benefit key suppliers like GE Aerospace, Howmet, Hexcel, and Woodward, with Wall Street expecting strong EPS growth for those companies in 2027 and 2028. However, our master report maintains a WAIT rating on Boeing itself, noting that the transition to higher production rates and certification of the 737 MAX 7 and 10 remain regulator-controlled and unproven. The pivot point referenced in the article is not a fundamental change for Boeing but rather an extension of the existing recovery narrative that hinges on FAA approvals and execution. While the supplier optimism is understandable given Boeing's backlog and delivery momentum, Boeing's own valuation at 30.2x EV/EBITDA lacks a margin of safety and leaves little room for error. Therefore, the news reinforces the positive trajectory for the supply chain but does not alter the core thesis that Boeing's recovery is conditional and not yet fully priced for upside.

Implication

The supplier upside is real if Boeing executes on its production and certification milestones, but Boeing's own equity still faces regulatory and execution risks that warrant patience. We continue to rate BA a WAIT, with an attractive entry near $210 and a trim above $255, as the stock already prices in a smooth recovery. Monitoring key catalysts such as FAA certification of the North Line and MAX 7/10, along with any new charges on 777X or VC-25B, will be critical before turning more constructive. The Motley Fool article does not change our fundamental view; it merely underscores that the recovery narrative is gaining traction in the supply chain, which could support those names. For Boeing, we need clearer evidence of cash conversion and debt reduction before upgrading.

Thesis delta

The news article does not materially shift our investment thesis for Boeing. While it highlights positive momentum for suppliers, Boeing itself still faces the same regulatory gating factors and execution risks that underpin our WAIT rating. The core thesis remains that Boeing's recovery is conditional on FAA approvals and certification, and current valuation offers limited margin of safety.